|
|
Strategic Analysis of the South African Paediatric Vaccines MarketsPublished by: Frost & Sullivan Published: Feb. 18, 2008 - 138 Pages Table of Contents
AbstractThis Frost & Sullivan research service titled Strategic Analysis of the South African Paediatric Vaccines Markets provides an overview of the South African healthcare industry in the context of paediatric vaccines as divided between the private and public sector. The research reveals the size of the market in both sectors as well as the competitors operating within this market. In this research, Frost & Sullivan's expert analysts thoroughly examine the South African public and private paediatric vaccines sectors.This analysis is available through our Pharmaceuticals and Biotechnology Growth Partnership Services programme. With this programme, clients receive industry-leading market research such as this, along with technical and econometric data and many interactive features including Analyst Inquiry Time and Client Councils. Market Overview Cost-effective Combination Vaccines Offer Tremendous Growth Potential Vaccines, especially paediatric vaccines, are among the fastest growing sectors in the pharmaceutical industry. Immunising populations, especially children, against life-threatening diseases offers a cost-effective manner of managing disease, particularly in developing countries where the disease burden is usually more severe than the developed world; vaccinations can save thousands of lives daily. The emergence of combination vaccines has revolutionised the South African paediatric vaccines industry. "The current trend in the paediatric vaccine market is to combine existing vaccines - these combination vaccines have caused a substantial increase in market revenues," notes the analyst of this research. "Growth in the South African private paediatric sector has risen significantly due to combination vaccines available in the market." Combination vaccines consist of up to nine antigens against various diseases incorporated into one vaccine, leading to fewer injections per immunisation, higher coverage rates and broader disease coverage. Another emerging trend is that of therapeutic vaccines. Vaccine manufacturers are ploughing significant capital and effort into designing innovative vaccines that can treat/prevent HIV, malaria and cancer, among other diseases. DNA technologies are being used to develop these advanced, novel vaccines. Vaccines are essential to finding cures for major diseases including HIV/AIDS and malaria. They are also useful in preventing the occurrence of certain diseases through providing enhanced immunity. For instance, vaccines limit pneumococcal disease - a disease caused by a streptococcus strain that builds up resistance against antibiotics and leads to the death of almost 800,000 children annually across the globe. Private Paediatric Vaccines Sector Represents High-margin, Low-volume Model, while Public Sector Represents High-volumes, Low-margin Model In South Africa, the paediatric vaccine market within the private sector has increased significantly over the last three to four years. This has been due to the launch of new combination and novel vaccines not covered by the government’s extended immunisation programme (EPI). In South Africa, the biggest challenge is to serve the public market through the government’s EPI. Although revenues are high, volumes are low in the private sector; in the public sector, this model is reversed. Government’s price-sensitive contracts, slow adoption of new technology and question marks around the disease burden of these new vaccines make it challenging for manufacturers to supply paediatric vaccines to the public sector. The government revises the EPI programme annually, but due to a tight budget allocated to paediatric vaccines, the process of adopting new vaccines into the programme relies on the cost of the vaccines and the severity of the disease burden that can be prevented by these vaccines. Vaccine manufacturers can overcome this challenge by reducing the manufacturing costs. "Optimising processes in research and development to be more cost effective will allow manufacturers to reduce the price of paediatric vaccines and boost their chances of entering the EPI programme," advises the analyst. "Apart from cost, it is important to justify the vaccine; paediatric vaccines are only accepted by government if the specific disease burden covered by the vaccine is severe enough - combination and ‘novel’ vaccines can play a huge role here. Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||